| Many players in BCL-2 family affairs T Moldoveanu, AV Follis, RW Kriwacki, DR Green Trends in biochemical sciences 39 (3), 101-111, 2014 | 518 | 2014 |
| Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc DI Hammoudeh, AV Follis, EV Prochownik, SJ Metallo Journal of the American Chemical Society 131 (21), 7390-7401, 2009 | 254 | 2009 |
| Improved low molecular weight Myc-Max inhibitors H Wang, DI Hammoudeh, AV Follis, BE Reese, JS Lazo, SJ Metallo, ... Molecular cancer therapeutics 6 (9), 2399-2408, 2007 | 253 | 2007 |
| Discoveries and controversies in BCL‐2 protein‐mediated apoptosis JH Zheng, A Viacava Follis, RW Kriwacki, T Moldoveanu The FEBS journal 283 (14), 2690-2700, 2016 | 250 | 2016 |
| Large-scale assessment of binding free energy calculations in active drug discovery projects CEM Schindler, H Baumann, A Blum, D Böse, HP Buchstaller, ... Journal of Chemical Information and Modeling 60 (11), 5457-5474, 2020 | 224 | 2020 |
| Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules AV Follis, DI Hammoudeh, H Wang, EV Prochownik, SJ Metallo Chemistry & biology 15 (11), 1149-1155, 2008 | 206 | 2008 |
| Dynamic Protein Interaction Networks and New Structural Paradigms in Signaling V Csizmok, A Viacava Follis, RW Kriwacki, JD Forman-Kay Chemical Reviews, 2016 | 205 | 2016 |
| PUMA binding induces partial unfolding within BCL-xL to disrupt p53 binding and promote apoptosis AV Follis, JE Chipuk, JC Fisher, MK Yun, CR Grace, A Nourse, K Baran, ... Nature chemical biology 9 (3), 163-168, 2013 | 198 | 2013 |
| Discovery of evobrutinib: an oral, potent, and highly selective, covalent Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of immunological diseases RD Caldwell, H Qiu, BC Askew, AT Bender, N Brugger, M Camps, ... Journal of Medicinal Chemistry 62 (17), 7643-7655, 2019 | 120 | 2019 |
| Pin1-induced proline isomerization in cytosolic p53 mediates BAX activation and apoptosis AV Follis, F Llambi, P Merritt, JE Chipuk, DR Green, RW Kriwacki Molecular cell 59 (4), 677-684, 2015 | 109 | 2015 |
| Discovery of novel Myc− Max heterodimer disruptors with a three-dimensional pharmacophore model G Mustata, AV Follis, DI Hammoudeh, SJ Metallo, H Wang, ... Journal of medicinal chemistry 52 (5), 1247-1250, 2009 | 101 | 2009 |
| The DNA-binding domain mediates both nuclear and cytosolic functions of p53 AV Follis, F Llambi, L Ou, K Baran, DR Green, RW Kriwacki Nature structural & molecular biology 21 (6), 535-543, 2014 | 96 | 2014 |
| Small-molecule perturbation of competing interactions between c-Myc and Max AV Follis, DI Hammoudeh, AT Daab, SJ Metallo Bioorganic & medicinal chemistry letters 19 (3), 807-810, 2009 | 72 | 2009 |
| Regulation of apoptosis by an intrinsically disordered region of Bcl-xL AV Follis, F Llambi, H Kalkavan, Y Yao, AH Phillips, CG Park, FM Marassi, ... Nature chemical biology 14 (5), 458-465, 2018 | 50 | 2018 |
| Intrinsic protein flexibility in regulation of cell proliferation: advantages for signaling and opportunities for novel therapeutics AV Follis, CA Galea, RW Kriwacki Fuzziness: Structural Disorder in Protein Complexes, 27-49, 2012 | 39 | 2012 |
| Identification and characterization of an allosteric inhibitory site on dihydropteroate synthase DI Hammoudeh, M Daté, MK Yun, W Zhang, VA Boyd, A Viacava Follis, ... ACS Chemical Biology 9 (6), 1294-1302, 2014 | 37 | 2014 |
| Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit H Qiu, L Liu-Bujalski, RD Caldwell, AV Follis, A Gardberg, A Goutopoulos, ... Bioorganic & Medicinal Chemistry Letters 28 (17), 2939-2944, 2018 | 24 | 2018 |
| Centrality of drug targets in protein networks A Viacava Follis BMC bioinformatics 22, 1-29, 2021 | 17 | 2021 |
| Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk R Caldwell, L Liu-Bujalski, H Qiu, I Mochalkin, R Jones, C Neagu, ... Bioorganic & Medicinal Chemistry Letters 28 (21), 3419-3424, 2018 | 17 | 2018 |
| Discovery of potent and selective reversible Bruton’s tyrosine kinase inhibitors H Qiu, Z Ali, A Bender, R Caldwell, YY Chen, Z Fang, A Gardberg, ... Bioorganic & medicinal chemistry 40, 116163, 2021 | 12 | 2021 |
Richard KriwackiSt. Jude Children's Research HospitalVerified email at stjude.org
